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ABSTRACT
We have developed a cost-effective, highly parallel
method for purification and functionalization of
50-labeled oligonucleotides. The approach is based
on 50-hexa-His phase tag purification, followed by
exchange of the hexa-His tag for a functional group
using reversible reaction chemistry. These methods
are suitable for large-scale (micromole to millimole)
production of oligonucleotides and are amenable to
highly parallel processing of many oligonucleotides
individually or in high complexity pools. Examples of
the preparation of 50-biotin, 95-mer, oligonucleotide
pools of >40K complexity at micromole scale are
shown. These pools are prepared in up to  16%
yield and 90–99% purity. Approaches for using this
method in other applications are also discussed.
INTRODUCTION
Puriﬁcation and modiﬁcation of synthetic oligonucleotides
are fundamental technologies required for many applica-
tions in the life sciences industry. The development of
efﬁcient techniques for large-scale oligonucleotide func-
tionalization and puriﬁcation is of great interest due to
the increased demand for labeled oligonucleotides in
many genomics applications, including genomic assays,
gene synthesis and oligonucleotide-based drugs/therapeut-
ics (1). Puriﬁcation strategies perform the following func-
tions: (i) separation of full-length oligonucleotides from
incomplete products; (ii) removal of products that are
not completely deprotected, or that are depurinated or
dimerized; (iii) desalting; (iv) and removal of cleaved
blocking groups. Common puriﬁcation methods include
alcohol-based precipitation, thin-layer chromatography
(TLC), ion-exchange and reverse-phase Fast Protein
Liquid Chromatography (FPLC), puriﬁcation cartridges
(oPC, etc.), PolyAcrylamide Gel Electrophoresis (PAGE)
gels, puriﬁcation by polymerization (2–4), ﬁnal
‘Trityl-ON’ option followed by HPLC puriﬁcation or
phase tags such as Fluorous or biotin (5,6). The general
strategy of phase tags is based on traditional solid-phase
oligonucleotide synthesis, followed by puriﬁcation using a
50-terminal phase tag. Each step of the synthesis is
followed by a capping step in order to prevent deletion
sequences from accumulating. The phase-tag is added at
the end of the synthesis, resulting in a mixture of
full-length, phase-tagged oligonucleotide and non-tagged
deletion sequences (4,7,8). Subsequently, the tagged oligo-
nucleotide is bound to a solid phase (e.g. Fluorous or
polymer), undesired capped sequences are removed by
washing and the puriﬁed, full-length, tagged oligonucleo-
tide is released. The appropriate puriﬁcation method or
combination of puriﬁcation methods depends on its appli-
cation, the size of the oligonucleotide, the degree of purity
required, the quantity and number of oligonucleotides to
be puriﬁed, time available and the cost of the method
(http:/www.abrf.org/ABRFNews/1992/June1992/
jun92oligo.html) (9).
We recently described an oligonucleotide synthesis tech-
nology that can produce >40K oligonucleotides
(10–120-mers) per day with an average yield of 10nmol
per oligonucleotide (10). These oligonucleotides are used
in DNA microarray production (11), genomic-based
assays (12), targeted sequencing (TS) applications (13),
decoding arrays (14), Inﬁnium and GoldenGate
genotyping assays (15–20) and many other applications.
For many of these, a high degree of puriﬁcation and func-
tionalization is required. For example, building a ﬁxed-set,
targeted exome sequencing product requires a pool of
>300K oligonucleotides in large quantities (micromole to
millimole) with >95% biotin-labeling. Although many
puriﬁcation methods can deliver highly pure and function-
alized oligonucleotides, current approaches cannot purify
large quantities of pools of 50-functionalized oligonucleo-
tides at low cost and in a fast, highly parallel fashion. The
need is especially great for oligonucleotides >80-mers, as
puriﬁcation becomes more challenging due to smaller size
differences between desired and truncated products.
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and preparation methods for individual or highly complex
pools of 50-biotinylated oligonucleotides. The methods are
based on (i) 50-hexahistidine phase tag (50-hexa-His) oligo-
nucleotide puriﬁcation and (ii) exchanging the hexa-His
tag for a biotin group (21). We demonstrate for the ﬁrst
time that the puriﬁcation scale can be matched with the
oligonucleotide synthesis scale. Additionally, we demon-
strate that pools of >40K oligonucleotides can be puriﬁed
and derivatized at the 50 end simultaneously. The method
is highly automatable, scalable, cost-effective and relative-
ly independent of oligonucleotide length.
MATERIALS AND METHODS
Oligonucleotides with a 50-aldehyde functional group were
synthesized on a custom-built continuous oligonucleotide
synthesizer at Illumina, Inc. at an average yield of 10nmol
per oligonucleotide (10). Aldehyde modiﬁers such as 50
benzaldehyde-modiﬁer-C2 phosphoramidite and
5-formylindole-CE phosphoramidite were suitable in the
described synthesis scheme. The oligonucleotides were
concentration-normalized and pooled to 42K complexity
using a Microlab Star Hamilton robot. The oligonucleo-
tides were received in 0.1  TE buffer. A single oligo-
nucleotide with a 50-aldehyde functional group was
purchased from TriLink, Inc. and delivered dry. This
oligonucleotide (50ALD/GGAATACAGTTGGCTGAT
GGTGGATGGCTCATACCCTCCAATGATGGAAA
GGCTGGAAAAGAAGAATTTTATAGGGCTCTGT
GTGACACTCCAGG) was used to characterize the chem-
ical transformations and was processed in a similar manner
as the pools of oligonucleotides. Plasticware and other
miscellaneous laboratory equipment were purchased from
Pierce, VWR, Millipore or Cole-Parmer. All other reagents
were purchased from Sigma-Aldrich, Dojindo Molecular
Technologies, Solulink, Clontech Laboratories and Life
Technologies.
Synthesis of 50-hexa-His labeled oligonucleotides
300ml of the 42K pool of 50-aldehyde-labeled oligo-
nucleotides (100mM) was transferred to two aliquots in
225ml centrifuge tubes and precipitated with cold
ethanol/sodium acetate. The pellet was washed once
with 25ml of cold 70% ethanol and dried overnight in a
vacuum oven set at room temperature. The pellet was re-
dissolved in 150ml of 1M citrate buffer at pH 6.0, and an
aliquot was quantiﬁed by optical absorbance spectroscopy
on a NanoDrop ND-1000 UV-Vis spectrophotometer.
Next, 150ml of 10M urea solution was added, bringing
the total concentration of oligonucleotides to 100mMi n
the solution. Subsequently, a 20-to-1 molar excess of
HyNic/PEG2/Hexa-His (Solulink PN SP-E001-005) was
added. 0.66g of HyNic/PEG2/Hexa-His was dissolved in
1ml of 1M citrate buffer at pH 6.0, and added to the
reagent mix. Next, 2.1g of neat aniline was added for a
ﬁnal aniline concentration of 100mM in the solution. The
tube was capped and placed on a rotisserie for 1h at room
temperature. Next, the oligonucleotides were precipitated
with cold ethanol/sodium acetate (dividing the reaction
into 6 50ml aliquots, and adding 150ml of cold
ethanol to each aliquot), and washed three times with
25ml of cold 70% ethanol and then dried in a vacuum
oven set at room temperature for 4h. The pellets of each
aliquot were redissolved in 50ml of pre-warmed, HPLC-
grade water and pooled.
Puriﬁcation of 50-hexa-His labeled oligonucleotides
Nickel–resin was obtained from Clontech (His60 Ni
Superﬂow Resin, Clontech PN 635659). Next, 200ml of
pre-homogenized Ni–resin slurry was added to each of the
two separate 225ml centrifuge tubes. Each tube was cen-
trifuged at 1200 rcf on an Eppendorf 5810 centrifuge for
5min. The liquid was removed by aspiration and pellets
were washed with 100ml of a solution of 5  Phosphate
Buffered Saline (PBS) buffer (pH 7.4) containing 8M
urea. The washing was repeated three times to equilibrate
the resin. In all, 25ml of the 50ml of the post-His conver-
sion reaction was placed into each centrifuge tube. An
additional 75ml of the 5  PBS buffer containing 8M
urea was added into each centrifuge tube of equilibrated
slurry. The tubes were capped, and placed on the rotisserie
at room temperature for a minimum of 4h.
The tubes were then centrifuged at 1200 rcf for 5min at
room temperature. The liquid was removed by aspiration
and discarded. The resin was transferred to a plastic
Buchner vacuum ﬁlter ﬂask (Nalgene, from VWR) and
washed with 500ml of 1  PBS (pH 7.4) containing
20mM imidazole. Next, the resin was washed with
200ml of 0.01N NaOH. The resin was then washed with
1L of 1  PBS (pH 7.4) containing 20mM imidazole. The
resin was split into two aliquots and transferred to new
225ml centrifuge tubes. To each tube was added 100ml of
500mM imidazole and 1  PBS buffer. The tubes were
placed on the rotisserie for 5min and centrifuged for
5min at 1200 rcf. The liquid was aspirated and collected.
The resin was then transferred to a Buchner vacuum ﬁlter
ﬂask and washed, in parts, with 500ml of 500mM imid-
azole solution and 1  PBS buffer. The collected washes
were concentrated down to  15ml using a Centricon 70
(10k MWCO, Millipore PN UFC701008) centrifugal dia-
lysis assembly. The solution was washed with 4 50ml
HPLC-grade water, concentrating after each wash with
the Centricon centrifugal dialysis assembly. The ﬁnal
solution was concentrated to  20ml and isolated.
A1 0ml aliquot of the concentrated solution was quan-
tiﬁed using the NanoDrop instrument, and 20ml of the so-
lution at 10mM concentration was sent to Novatia LLC
(www.enovatia.com) for LC–MS analysis as a modiﬁed
95-bp oligonucleotide. Another 10ml aliquot was used
for the FPLC analysis, as described below.
Synthesis of 50-biotin labeled oligonucleotides
The hexa-His product was transferred to a new 225ml
centrifuge tube. Subsequently, 150ml of 1M citrate
buffer at pH 6.0 and 150ml of 10M urea solution were
added. A 10-fold molar excess of the hydrazide-HyNic-
biotin (Solulink) was used relative to the total amount
of oligo in the solution. For 30mmol of total
oligonucleotide, 300mmol of the biotin-oxo-amine was
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tube was capped and placed on a rotisserie at room tem-
perature for 4h. The oligonucleotides were then
precipitated out using cold ethanol and sodium acetate,
the pellet was washed with 3 25ml of cold 70%
ethanol, and the pellet was dried in a vacuum oven over-
night at room temperature. The pellet was redissolved in
pre-warmed 50ml HPLC-grade water. The 50ml solution
of biotinylated oligonucleotides was mixed with the
Nickel–resin slurry as described above, except the
ﬂow-through, containing the biotinylated oligonucleo-
tides, was collected and retained. The ﬂow-through was
concentrated using a Centricon 70 centrifugal dialysis
apparatus as described above, and washed 4 50ml
with HPLC-grade water down to a ﬁnal concentration
of  25ml in HPLC-grade water. A 10ml aliquot of the
ﬁnal puriﬁed solution was quantiﬁed with optical absorb-
ance spectroscopy on a NanoDrop instrument, and for
the LC–MS analysis and FPLC analyses. The ﬁnal yields
for pool 1–8 were 2.49, 2.43, 2.74, 2.48, 2.68, 3.13, 2.18,
2.16mmol, respectively. The ﬁnal process yields for the
biotin oligonucleotide pools 1–8 were 8.3, 8.1, 9.2, 9.0,
9.0, 10.5, 7.3 and 7.2%, respectively. A 15.8% overall
yield for pool 7 or 8 was observed when the exchange
reaction was performed with biotin-oxo-amine (Dojindo
PN A305-10).
FPLC analysis
FPLC analysis was performed with a GE Akta Explorer
FPLC system ﬁtted with a Nickel–resin cartridge (HisPur
Ni-NTA Chromatography Cartridge, Pierce PN 90099),
using a method similar to that described by the column
vendor for FPLC analysis of hexa-His-labeled biomol-
ecules. The highest quality imidazole (BioUltra, Sigma-
Aldrich, 56749) gave the best performance in our hands.
The signal of the oligonucleotides was monitored at 260
and 280nm. Integration was performed using the Agilent
ChemStation software using classical baseline correction,
standard tangent skim mode, tail peak skim height ratio is
0, front peak skim height ration is 0, skim valley ratio is 20
and peak to valley ratio is 500. The samples were prepared
as 50ml volume in water at 20mM concentration. The ﬂow
rate was set at 0.2ml/min. The binary solvent proﬁle was
100% Buffer A until after the non-hexa-His-containing
biomolecules were eluted ( 25min), then 100% Buffer B
to elute off the hexa-His-containing biomolecules. Buffer
A consisted of 50mM phosphate, pH 7.4, 20mM imid-
azole and 300mM NaCl. Buffer B consisted of 50mM
phosphate, pH 7.4, 300mM imidazole and 300mM NaCl.
RESULTS
The approach of the method is depicted in Scheme 1. The
method is based on synthesizing 50-aldehyde-modiﬁed
oligonucleotides, and utilizing the aldehyde group for
hexa-His phase-tag attachment, followed by 50-Biotin
derivatization using an exchange reaction (21). We
synthesized >300K different 50-aldehyde-modiﬁed oligo-
nucleotides of 95bp in length using a custom built
continuous oligonucleotide synthesizer (10,22). The
sequences of the oligonucleotides were designed against
the UCSC Human Exome (NCBI/Hg19 reference
genome), enabling the ﬁnal biotin-oligonucleotides to be
used in whole-exome TS applications (Steemers,F.J., in
preparation; 23,24). The oligonucleotides were subse-
quently pooled into eight pools of 42K complexity.
Each pool contained oligonucleotides of a speciﬁc
GC-range (Table 1), allowing speciﬁc GC-effects to be
observed during the synthesis and puriﬁcation. The
aldehyde oligonucleotide pools were functionalized with
a hexa-His tag using Hynic/Peg2/Hexa-His (25). The con-
version efﬁciency based on FPLC and LC-MS analysis
was >80% per pool. Each hexa-His-tagged oligonucleo-
tide pool was subsequently puriﬁed using a Ni–resin (26).
Oligonucleotides that lacked the hexa-His-tag, truncated
oligonucleotides and synthesis failures, were removed by
high-pH (0.01N NaOH) washing. The hexa-His oligo-
nucleotides were eluted using an imidazole elution with
Dithiothreitol (DTT), (10mM) (27). Gel analysis showed
that the hexa-His product was obtained as the majority
product (Figure 1a). Interestingly, we observed a small but
gradual reduction in purity of the pools for the higher
percent GC pools. For example, pool 1 has a purity of
95%, while pool 8 has a purity of 85% using FPLC
analysis. In the subsequent step, the hexa-His tag was
exchanged for a 50-biotin moiety using biotin-hydrazide
or biotin-oxo-amine (21). The conversion efﬁciency
based on FPLC and LC-MS analysis was >80%.
Unconverted hexa-His oligonucleotides were removed
using simple Ni–resin ﬁltration, and the ﬁnal biotin-
labeled oligonucleotides were obtained in  7–11% yield
for each of the pools using biotin-hydrazide. The purity
and yield of the pools were established by capturing the
FPLC trace signal (Figure 2). Overall, we obtained a
purity of 97–99% (pools 1–6), 95% (pool 7), 90% (pool
8) based on 260nm absorbance. Again, as observed with
the hexa-His oligonucleotide intermediate method, the
purity of the product decreased going from low to high
percent GC pools. Strikingly, a doubling of the ﬁnal yield
to  16% was observed for pools 7 and 8 when
biotin-hydrazide was substituted for biotin-oxo-amine.
These metrics were validated by using puriﬁed hexa-His
oligonucleotides as input material. Additional conﬁrm-
ation that the ﬁnal puriﬁed biotin-oligonucleotide pools
were indeed biotin-labeled was obtained using a
streptavidin shift assay using an agarose gel analysis
(Figure 1b). Measuring the reduction in gel migration
with excess streptavidin (+) versus no streptavidin ( )
showed that the majority of products shifted upon
addition of streptavidin, indicating that >95% of the
oligonucleotides were biotinylated. Supplementary
Figure 1c presents the streptavidin shift assay, except
with oligonucleotides that had been biotinylated directly,
without using the puriﬁcation process described herein. As
expected, only a very small amount of biotinylated oligo-
nucleotide was obtained, and with very low purity. Several
key steps in the protocol were identiﬁed to increase the
process yield. We found that adding urea to the
Ni-column/His-oligonucleotide binding step improves
yield by up to 20–70%, depending on the percent GC of
the pool. The higher percentage GC-pools yielded greater
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step, we observed yield improvements when the binding of
hexa-His oligonucleotide to Ni–resin was performed as
slurry instead of a traditional column format. Increased
binding time up to 4h contributed an additional  5% to
the yield improvement. The addition of urea in the
exchange reaction also showed a 20–70% yield increase.
Again, the higher percentage GC-pools yielded greater
yield improvement with the addition of urea.
To follow the chemical transformations of the oligo-
nucleotide puriﬁcation and functionalization process, mass
spectroscopy was performed on a single oligonucleotide
of same length and 50-aldehyde modiﬁcation. The oligo-
nucleotide was taken through the same process steps as
the oligonucleotide pools, and after each step the oligo-
nucleotide was analyzed by LC–MS (Novatia LLC). As
expected, the oligonucleotides were found to incorporate
the hexa-His tag at the aldehyde position after the ﬁrst
reaction, and then exchange the hexa-His tag for the biotin
functionality after the second reaction. Furthermore, the
LC–MS of the ﬁnal biotinylated product showed no
starting material, no hexa-His tag intermediate products
and no synthesis truncation anomalies (Supplementary
Figure 3a–d). In order to determine functionality of
the biotin-oligonucleotide pools, we evaluated the pools
with an in-house developed TS capture method for iso-
lating exonic regions (Truseq Exome Enrichment) in the
human genome (Steemers,F.J., in preparation). For a
given sequencing throughput, these targeted solutions
are attractive if one desires to sequence a subset of the
human genome at high coverage or sequence many
samples at a lower coverage. The TS assay workﬂow
consists of the following steps: (i) solution-phase anneal-
ing of biotin-oligonucleotides to Illumina sequencing
libraries; (ii) binding of annealed biotin-oligonucleotides/
libraries with magnetic streptavidin beads; (iii) stringency
washing; (iv) releasing the enriched libraries of interest
using denaturing conditions; and (v) sequencing the
enriched libraries using the Illumina Genome
Analyzer
TM (28). We have evaluated the performance of
the individual and combined biotinylated oligonucleotiode
pools in such applications. We observed efﬁcient and
Scheme 1. Synthesis and puriﬁcation scheme for pools of 50 biotin oligonucleotides
Table 1. Oligonucleotide pools and their %GC range
Pools %GC
Pool 1 15–37
Pool 2 37–42
Pool 3 42–46
Pool 4 46–49
Pool 5 49–50
Pool 6 50–55
Pool 7 55–61
Pool 8 61–88
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speciﬁcity), with relative uniform capture across the entire
Exome ( 90% of targeted bases were covered at 0.2  of
the mean coverage).
DISCUSSION
A novel method is described to make individual or pools
of puriﬁed 50 biotin-functionalized oligonucleotides.
The method is unique because puriﬁcation is facilitated
by means of a 50-hexa-His tag, which is then exchanged
for a biotin group. Hexa-His tag puriﬁcation had been
extensively applied previously to protein puriﬁcation;
however, its utility for oligonucleotide puriﬁcation has
not been demonstrated. The high-loading capacity of the
Ni–resin is exploited for purifying large (micromole)
amounts of oligonucleotides. Experiments carried out on
a Ni-slurry indicated that crude oligonucleotides, loaded
as high as 30mmol per 200ml of Ni-slurry, were readily
processed, resulting in product recovery of up to 16%
and purity of >90–99%. In contrast to prior work, this
new approach was successfully scaled-up to high Ni–resin
loadings while maintaining high purity and yields. These
results demonstrate that hexa-His puriﬁcation and ex-
change can be employed for large-scale oligonucleotide
separations at high column loading. The Ni–resin solid-
phase format is readily scalable and has a binding cap-
acity that can match micromole-to-millimole quantities
Figure 1. (a) Gel analysis of the puriﬁcation process of a 42K oligonucleotide pool: (1) unpuriﬁed aldehyde oligonucleotides, (2) wash from
Ni-column, (3) eluted hexa-His oligonucleotides. (b) Gel shift analysis of the biotinylated oligonucleotide pools 1–8 with (+) and without ( )
streptavidin.
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biotin-oxo-amine in the substitution reaction doubled the
yields for the ﬁnal product. This effect can be attributed to
the stronger nucleophilic nature of biotin-oxo-amine
compared with Hydrazide-biotin, and the irreversible
nature of the ﬁnal product with biotin-oxo-amine.
The yields were quite respectable, given the fact that
the starting full-length oligonucleotides were  80–90%
aldehyde-labeled (Smith, R. C., unpublished data), and
that the theoretical maximum yield for a full-length
95-mer is  38% based on an average stepwise coupling
efﬁciency of 0.99 per phosphoramidite addition.
Additionally, the crude aldehyde oligonucleotides con-
tained truncated products and impurities that were
included in the optical absorbance quantiﬁcation to estab-
lish the amount of starting material. An interesting obser-
vation is that the yield and purity are reduced with higher
percentage GC oligonucleotide pools. GC-dependent
inter- and intramolecular hybridization between the
pooled oligonucleotides is the most likely contributor to
these phenomena. It also explains why adding urea, a de-
naturant, helps improve yield and purity, especially for the
higher percent GC pools. The method is ﬂexible with
respect to the type of functional group or label added to
the 50 end of the oligonucleotide. Many nucleophiles in the
form of oxo-amino or hydrazide can be used to introduce
various chemical moieties using the exchange reaction.
Moreover, this same approach can be used to purify un-
labelled, full-length oligonucleotides, by using the
exchange reaction with a compound such as
methoxyamine. The ability to convert the hydrazone bond
to a dynamic state is key to its use as an exchangable
linker for the preparation of functionalized oligonucleo-
tides (21,29). Strong nucleophiles, i.e. oxo-amine, that
exchange the hexa-His group and form an irreversible
bond between the oligonucleotide and the functional group
are especially desirable. This results in higher yields and
ﬁnal product stability as compared with hydrazide-
functionalized groups (30). The hexa-His and biotin de-
rivatives were stable in our hands for at least 6 months.
A signiﬁcant beneﬁt of this approach is that the overall
cost of the puriﬁcation method is <10% of the oligo-
nucleotide synthesis cost. The process uses readily avail-
able reagents and equipment, allowing the method to be
adopted in laboratories that are minimally equipped.
This article describes the use of hexa-His puriﬁcation
and functional group exchange for attaching the function-
al group on the 50 end of long (>80-mers) oligonucleo-
tides. To the best of our knowledge, this is the ﬁrst
reported method to demonstrate a production-scale pro-
cess that can efﬁciently functionalize and purify pools of
oligonucleotides at micromole scale. The method
functionalizes only full-length oligonucleotides and efﬁ-
ciently removes truncated species like n 1. However,
the method does not remove depurinated, partial
deprotected and modiﬁed oligonucleotides. For many ap-
plications in the genomics ﬁeld, such purity is sufﬁcient.
We also demonstrate that this method effectively removes
closely related impurities lacking the 50-aldehyde function-
ality and other contaminants during the synthesis.
Additionally, we have shown that this method scales
with the binding capacity of Ni-column resin and can
therefore scale to millimole quantities. Ni–resins or alter-
native hexa-His binding resins are readily available in
various formats, including 96-well plates, columns and
magnetic beads. This ﬂexibility makes the process
amenable to highly parallel formats and automation so
that many individual oligonucleotides or pools of oligo-
nucleotides can be processed. We believe that this
approach is useful not only for the puriﬁcation of oligo-
nucleotides but also for other molecules such as carbohy-
drates, RNA, antibodies and proteins for which the
researcher desires high purity and the option of introduc-
ing functional groups. Finally, we have demonstrated that
the biotin–oligonucleotide pools are functional in TS
assays.
In summary, the key beneﬁts of this method are as
follows: (i) puriﬁcation cost is less than the oligonucleotide
cost; (ii) scalability, matching puriﬁcation scale with oligo-
nucleotide synthesis scale; (iii) applicability to 95bp and
potentially longer oligonucleotides; (iv) insensitivity to
various oligonucleotide synthesis impurities; (v) and ap-
plicability to pools of oligonucleotides.
We are currently exploring further puriﬁcation methods
by reacting the aldehyde oligonucleotide directly to a
hydrazide-functionalized solid phase. Releasing the oligo-
nucleotide into solution by a nucleophilic exchange reac-
tion yields a puriﬁed and functionalized product. One of
the beneﬁts compared to the solution approach is that any
hexa-His oligonucleotides not converted to biotinylated
oligonucleotide will remain on the solid support and there-
fore does not need to be removed by an additional
Ni-column afﬁnity puriﬁcation step. This reduces the
number of steps and simpliﬁes the workﬂow. An addition-
al beneﬁt of the solid-phase puriﬁcation is that a speciﬁc
amount of an individual oligonucleotide can be isolated
and puriﬁed using a ﬁxed amount of solid-phase. Such an
Figure 2. Normalized FPLC traces based on maximum peak height for
pool 2. Pool 2 with (i) the 50-aldehyde functionality, (ii) puriﬁed pool 2
with the hexa-His functionality and (iii) the puriﬁed pool 2 with the
biotin functionality.
e4 Nucleic AcidsResearch, 2012,Vol. 40,No. 1 PAGE 6 OF 7approach would allow concentration normalization across
individual oligonucleotides.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Figures 1c, 3a–d.
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